Skip to content

Beam Therapeutics BEAM Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-226.6%+48.0pp-274.6%+563pp-837.1%
Returns
Return on invested capital-39.4%+5.5pp-44.9%+14.4pp-59.3%
Efficiency
Asset turnover0.1×0.0×0.1×+0.1×0.0×0.0×0.0×
Liquidity
Current ratio17×+3.9×13.1×+7.1×-0.7×6.8×-2.1×8.8×+4.0×
Leverage
Debt-to-equity0.2×+0.1×0.1×0.0×0.2×0.0×0.1×0.0×0.1×-0.1×
Per Share
Book value per share$11.28-9.9%$12.52+32.9%$9.42-8.2%$10.26-20.1%$12.84+44.1%
Valuation
Market capitalization$2.43B-13.7%$2.81B+14.6%$2.46B+42.4%$1.72B-11.6%$1.95B-5.0%
Price / sales14.8×-5.3×20.1×-23.9×44.1×+15.5×28.6×-2.1×30.7×-1.7×
Price / book2.1×-0.2×2.3×-0.3×2.5×+0.9×1.6×-0.1×1.7×-1.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Beam Therapeutics's ratios come from?
Every ratio is computed from Beam Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.